- CODEN : IAJPBB
- issn 2349-7750
TITLE:
HIGH INCIDENCE OF REDUCED SERUM HDL CHOLESTEROL IN DIABETIC PATIENTS TREATED WITH ROSIGLITAXONE AND FIBRATE
AUTHORS:
Dr.Muhammad Awais, Dr Iqra Rauf, Dr Ali Hasan
ABSTRACT:
To evaluate the effect of rosiglitazone, fenofibrate, or their combined use on plasma lipids in normoglycemic healthy adults. Methods and Results. Subjects were randomized in a double-blind fashion to rosiglitazone + placebo, fenofibrate + placebo, rosiglitazone + fenofibrate, or matching double placebo. The between-group difference in the change in fasting TG, high-density lipoprotein cholesterol (HDL-C), LDL-C, and plasma apolipoproteins A-I, A-II, and C-III level were compared after 12 weeks of treatment. A total of 548 subjects were screened and 41 met the inclusion criteria. After 12 weeks of therapy, the median change in the triglyceride levels showed a significant reduction ranging from 47 to 55âmg per deciliter in the fenofibrate only and rosiglitazone/fenofibrate groups compared with placebo (ð = 0 . 0 4 9 6). However, the rosiglitazone only group did not show significant change in triglyceride level. The change in the Apo AII showed increase in all the treatment groups compared with placebo (ð = 0 . 0 0 9). There was also significant change in the Apo CIII that showed reduction of its level in the fenofibrate only and rosiglitazone/fenofibrate groups (ð = 0 . 0 0 0 3). Rosiglitazone does not appear to modulate hypertriglyceridemia in patients with elevated triglycerides independent of glucose metabolism. Keywords: Reduced Serum HDL; Rosiglitaxone; Fibrate
FULL TEXT
Approved Journal
NLM ID:101711216 [Serial]
Included in EuroPub database
ICV 2015 - 61.16
Indexed In
S.J Impact Factor:7.157
cosmos Impact Factor:4.153
ICMJE Recommendations
IP Indexing Impact Factor: 2.76
Cover Page
